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Abstract 
We define phosphovariants as genetic variations that change phosphorylation sites or their interacting 
kinases. Considering the essential role of phosphorylation in protein functions, it is highly likely that 
phosphovariants change protein functions and may constitute a proportion of the mechanisms by which genetic 
variations cause individual differences or diseases. We categorized phosphovariants into three subtypes and 
developed a system that predicts them. Our method can be used to screen important polymorphisms and help to 
identify the mechanisms of genetic diseases. 
Protein phosphorylation is involved in various important processes: development and learning at the 
organism level, and the cell cycle, differentiation, and apoptosis at the cellular level1,2. Phosphorylation can 
change the subcellular localization of a protein, its lifespan, and its affinity for other proteins or DNA3. 
Therefore, the addition or deletion of phosphorylation sites through phosphovariants can lead to functional 
variations in proteins that can result in phenotypic variations or genetic diseases. By our definition, 
phosphovariants are variations that change phosphorylation sites or their interacting kinases. We propose three 
subtypes of phosphovariants. First, some variations occur directly at phosphorylation sites, and these sites will be 
removed if the phosphoreceptors are replaced with amino acids other than serine, threonine, or tyrosine. 
Conversely, replacement of another amino acid with a serine, threonine, or tyrosine may add a new 
phosphorylation site. Second, variations adjacent to phosphorylation sites can result in the removal or addition of 
phosphorylation sites. Third, variations may change the kinases that recognize phosphorylation sites, without 
changing the phosphorylation site itself. We divided phosphovariants into type I, II, and III, respectively, 
according to the above descriptions (Fig. 1). 
We developed PredPhospho (version 2), a Web-based computer program that predicts phosphorylation 
sites, and PhosphoVariant, a database for human phosphovariants. Even the advanced laboratory techniques used 
to analyze phosphorylation sites, such as mass spectrometry (MS), cannot analyze all types of proteins4,5. For 
example, peptides that are either too small or too large in mass can be easily missed. Moreover, membrane 
proteins cannot be obtained in sufficient quantities for analysis5. Even when proteins can be analyzed with MS, it 
is very time consuming and expensive to make thousands of variant proteins and select the phosphovariants. 
PredPhospho can predict the phosphorylation sites in kinase-specific ways, using the support vector machines 
(SVMs) derived from statistical learning theory proposed by Vapnik and Chervonenkis in 19956. In our study, 
we searched for known phosphovariants and tried to predict other possible phosphovariants among human 
variations. 
Results 
Type I phosphovariants 
The substitution of phosphoreceptor amino acids with amino acids other than serine, threonine, or 
tyrosine causes the elimination of phosphorylation sites and can be classified as type I (–) phosphovariants 
according to our classification. We found 52 type I phosphovariants by matching the locations of the variations 
and those of phosphorylation sites registered in the Swiss-Prot database and the Human Protein Resource 
Database7,8 (HPRB, Table 1). Of these phosphovariants, 19 are known to cause Mendelian-inherited diseases 
and 18 are associated with cancers. Another 13 phosphovariants are polymorphisms. 
Conversely, new phosphorylation sites can be created by variations and we defined these as type I (+) 
phosphovariants. We found an example in the study of Nousiainen et al.9 The cell line that they used had a 
Gly766Ser mutation in the probable ATP-dependent RNA helicase DDX27 (Swiss-Prot ID, Q96GQ7), which 
was identified as phosphorylated. Similarly, the polymorphisms in Tables 1–3 are good examples of  the 
addition of phosphorylation sites by sequence variations. For example, if we postulate that the isoleucine at 
amino acid 571 of CTP synthase 1 (Swiss-Prot ID, P17812) is changed to serine, then it also represents a type I 
(+) phosphovariant, rather than a type I (–) phosphovariant (Table 1). 
Type II phosphovariants 
It is more difficult to find examples of type II phosphovariants than to find type I phosphovariants, 
because we cannot definitely say that a phosphorylation site is changed by a substitution near a phosphorylation 
site. However, when some kinases (although not all kinases) recognize phosphorylation sites, the specific amino 
acids near the phosphoreceptor are important. In Figure 2, we present sequence logos of phosphorylation site 
sequences for the CMGC kinase group. The proline residues at position +1 relative to the phosphorylation sites 
are important in the phosphorylation site sequences of the CMGC kinase group, especially the CDK kinase 
family and the MAPK kinase family. Most (84%) of the phosphorylation sites of the CMGC group registered in 
the Swiss-Prot database and the Human Protein Resource Database (91% of the CDK and 87% of the MAPK 
kinase families) have +1 proline residues. If the proline is substituted with another amino acid, it is highly 
probable that the adjacent phosphorylation site will be abolished. The phosphorylation site at Ser112 of 
peroxisome proliferator-activated receptor gamma protein (Swiss-Prot ID, P37231) is eliminated by the 
Pro113Gln substitution10. We found three other polymorphisms that abolish phosphorylation sites of the CMGC 
kinase group, but the removal of these phosphorylation sites has not yet been confirmed (Table 2). The presence 
of specific amino acids does not directly affect phosphorylation by kinases other than those of the CMGC kinase 
group, but sequences near the phosphorylation site must be considered. Kinases recognize the residues 
surrounding the target phosphorylation site, and the amino acids bordering phosphorylation sites are, in turn, 
affected by other nearby residues11. Hence, when the relevant kinases are not members of the CMGC kinase 
group, it is difficult to predict type II phosphovariants simply by database matching, without specific programs 
that predict phosphorylation sites. 
Type III phosphovariants 
Type III phosphovariants are those variations that change only the type of kinase involved, without 
affecting the phosphorylation site itself. For example, Ser386 of the tyrosine protein phosphatase, non-receptor 
type 1 (PTPN1, Swiss-Prot ID, P18031) is phosphorylated by cell division cycle 2 (CDC2) kinase, a member of 
the CMGC kinase group, and by casein kinase 2 (CK2), a member of the “Other” kinase group12,13. The 
Pro387Leu substitution reduces 75% of the phosphorylation by CDC2 in vitro14. However, it has not been 
confirmed that Pro387Leu inhibits the recognition of Ser386 by CK2. Only about 5% of the sites phosphorylated 
by CK2 that are registered in the Swiss-Prot database or HPRD have a proline residue at position +1 relative to 
the phosphorylation site. There is also no known consensus sequence for CK2 that contains proline at that 
location15. Therefore, we infer that the proline residue is not essential for phosphorylation by CK2 and that 
Pro387Leu will have little effect on phosphorylation by CK2. Therefore, we consider Pro387Leu of PTPN1 a 
type III phosphovariant because it inhibits the recognition of Ser386 by CDC2 kinase but has little effect on its 
phosphorylation by CK214,16. 
Kinases that recognize serine and threonine differ from the kinases that recognize tyrosine. The 
substitution of phosphorylated serine or threonine for tyrosine, or vice versa, can remove a phosphorylation site 
or change the type of kinase that recognizes it. Changes between serine and threonine can also cause changes in 
the phosphorylation site and the responsive kinase. Therefore, the phosphovariants in Table 3b are either type I 
or type III phosphovariants. 
Performance of PredPhospho and Scansite 
We developed prediction models for six kinase groups and 18 kinase families. Their accuracy ranged 
from 70.80% to 94.67% at the kinase family level and from 71.77% to 91.18% at the kinase group level 
(Supplementary Table 2 online). We tested our prediction models using two real laboratory data sets compiled  
with MS. For the six kinase group models, the sensitivities were 79.40% with data set I and 75.47% with data set 
II, but the specificities were as low as 60.62% for data set I and 61.04% for data set II because of the 
accumulation of false negatives by all six kinase group models. When we modified the specificity to > 95% (see 
Supplementary Material for the modification of the specificity for each model), the specificities increased to 
72.09% and 72.39%, respectively, for each data set, whereas the sensitivities decreased to 73.24% and 65.76%, 
respectively (Table 4). At a specificity of > 99%, the specificities changed to 95.79% and 96.62%, respectively, 
and the sensitivities to 23.39% and 20.05%, respectively. Scansite is a widely used Web-based prediction 
software for phosphorylation sites17. We also tested Scansite with the same data sets. When we applied Scansite 
with the low-stringency option to the data sets, the specificities were 52.60% and 57.06%, respectively, and the 
sensitivities were 84.47% and 83.92%, respectively, whereas with the high-stringency option, the specificities 
were 96.77% and 95.71%, respectively, and the sensitivities were 16.39% and 13.60%, respectively. The 
performance of PredPhospho with no modification to the specificity is similar to that of Scansite used with the 
low-stringency option. The performance of PredPhospho with a specificity of > 99% was similar with that of 
Scansite used with the high-stringency option. The data sets were analyzed in the same way with the 18 kinase 
family models (Table 4). The family-wise prediction generally had greater sensitivity and lower specificity than 
the group-wise prediction. 
Phosphovariants predicted with PredPhospho and Scansite 
The numbers of phosphovariants predicted with PredPhospho and Scansite are shown in Table 5. In the 
supplementary data (online), we present the results for phosphovariants that were predicted with PredPhospho 
with the > 99% specificity option. The sensitivity and specificity of the prediction of type I phosphovariants will 
be the same as the result shown in Table 4, because we can predict type I phosphovariants simply by the 
location of phosphorylation sites, with no knowledge of the kinds of kinases involved. The notions of type II and 
type III phosphovariants include the kinds of kinases that recognize the phosphorylation sites. Therefore, the 
prediction of type II and III phosphovariants differs from that of type I. Not only the phosphorylation site but 
also the type of kinase must be identified, because important amino acid residues flanking the phosphorylation 
sites, which guide kinases to the site, may differ according to the kinase involved. Therefore, the general 
performance of our prediction of type II and type III phosphovariants will be somewhat different from those 
shown in Table 4. Instead, the performance of the each kinase-specific prediction can be judged from the 
performances shown in Supplementary Table 2 (online). 
The proportion of phosphovariants predicted by PredPhospho is shown in Table 6. These data were 
selected with the > 99% specificity option at the kinase family level, and are related to the confirmed 
phosphorylation sites in human or orthologous proteins, for which kinase information is not yet available. As 
described in the Supplementary Material (online), only phosphorylation sites with available kinase information 
were used as training models for PredPhospho. Hence, the phosphorylation sites in Table 6 are predicted ones 
with PredPhospho, because the phosphorylation sites were not included in the training data for PredPhospho. If a 
specific site is shown to be a phosphorylation site in human or orthologous proteins, then the site is definitely 
located on the surface of the protein, and therefore, is accessible to a kinase. The predicted phosphovariants 
related to a proven phosphorylation site are more likely to be true than are those related to an unproven 
phosphorylation site. Numerous phosphorylation sites in humans or other species are constantly being identified. 
The priority for further research among predicted phosphovariants can be decided based on the confirmation of 
specific phosphorylation sites. 
Discussion 
Changes in phosphorylation sites cause various diseases by numerous mechanisms. Some proven 
mechanisms of the phosphovariants shown in Tables 1–3 are related to changes in the protein’s affinity for 
DNA, inducing hyperphosphorylation and the inhibition of ubiquitinization. For example, microphthalmia-
associated transcription factor (MITF) activates the transcription of the tyrosinase gene. The Ser405Pro change 
in MITF eliminates the phosphorylation site at Ser405 and inhibits the binding of MITF to DNA. As a result, the 
mutation causes Waardenburg syndrome type IIa, the symptoms of which include depigmentation and 
sensorineural hearing loss18. Abnormal phosphorylation can also cause disease by increasing phosphorylation at 
other sites. The hyperphosphorylation of tau protein induces neurofibrillary tangles and the accumulation of 
these tangles can result in Alzheimer’s disease and frontotemporal dementia (FTD). Paradoxically, serine 
threonine protein kinase N (PKN) interrupts the phosphorylation of other sites by phosphorylating Ser637 and 
Ser669 of tau protein19. The mutations Ser637Phe and Ser669Leu of tau protein eliminate the recognition sites 
for PKN and induce the hyperphosphorylation of tau protein. FTD and the respiratory failure with dementia are 
known to be related to Ser637Phe and Ser669Leu, respectively20,21. Phosphorylation at Ser32 of NF-κB inhibitor 
α (Swiss-Prot ID, P25963) causes ubiquitinization and results in the activation of NF-κB22. The Ser32Ile 
substitution of NF-κB inhibitor α (Swiss-Prot ID, P25963) eliminates the phosphorylation site at Ser32. 
Consequently, the ubiquitinization of NF-κB inhibitor α is inhibited by the Ser32Ile variant of NF-κB inhibitor 
α and NF-κB cannot be activated. The Ser32Ile variant of NF-κB inhibitor α causes autosomal dominant 
anhydrotic ectodermal dysplasia with immunodeficiency23. These are a few examples of phosphovariants. 
Considering the numerous functional roles played by phosphorylation in vivo, there must be many mechanisms 
by which phosphovariants can cause specific diseases, and these must be identified. 
Some phosphovariants do not cause Mendelian-inherited diseases, but change an individual’s 
susceptibility to disease. The Pro113Gln substitution (dbSNP id, rs1800571) of peroxisome proliferator-
activated receptor gamma (Swiss-Prot ID, P37231), which eliminates the phosphorylation site at Ser112, is 
known to cause obesity10. The Pro387Leu substitution (dbSNP ID, rs16995309) of tyrosine-protein phosphatase 
non-receptor, type 1 (Swiss-Prot ID, P18031) is associated with type II diabetes mellitus14,16. We only found 
these two polymorphic phosphovariants that are related to disease susceptibility. As shown in Tables 1–3, 21 
phosphovariants are polymorphisms, and the biological significance of 19 of these polymorphisms is not yet 
known. In addition, we do not know the biological significance  of most of the polymorphic phosphovariants 
predicted in our study. Considering the importance of phosphorylation in protein function, polymorphic 
phosphovariants may well be involved in specific diseases or phenotypes. 
Apart from the characteristics of the three types of phosphovariants already suggested, there are other 
fundamental differences between the type I and other phosphovariants. Type I phosphovariants completely add 
or remove a phosphorylation site because kinases can only donate a phosphor moiety to an amino acid with a 
hydroxyl group. However, type II and III phosphovariants can significantly affect kinase kinetics without 
completely changing the kinase’s recognition site. For example, the Pro387Leu substitution of PTPN1 removes 
only 75% of the phosphorylation of Ser386 by CDC2 kinase in vitro, rather than 100% (Table 3)14. 
We can explain phenotypic variations and diseases in terms of phosphovariants in more cases than we 
have anticipated. Of the human proteins registered in the Swiss-Prot database, 25.5% are phosphoproteins and 
60.9% of these phosphoproteins have multiple phosphorylation sites. The protein with the greatest number of 
confirmed phosphorylation sites is the serine/arginine repetitive matrix protein 2 (Swiss-Prot ID, Q9UQ35), with 
195 phosphorylation sites. Although we could only determine 62 phosphovariants with a database search, many 
more phosphovariants must exist. Furthermore, if we count the mutations that add phosphorylation sites and the 
type II and III phosphovariants that cannot be found without specific programs, the number of mutations 
associated with changes in phosphorylation sites is much greater. We did not consider haplotypes in this study, 
for simplicity. However, if two or more  nearby variations are frequently linked, a nearby phosphorylation site 
can be altered, although each variation individually does not affect the phosphorylation site. Therefore, 
phosphovariants may account for a much greater proportion of human variation than we have anticipated. 
Several issues must be resolved in future studies. Type II and type III phosphovariants can be 
interchanged. For example, removed phosphorylation sites associated with type II (–) phosphovariants predicted 
with PredPhospho may be recognized by kinases that are not included in our prediction models. In such cases, 
these variations are type III phosphovariants, not type II (–). Conversely, if a phosphorylation site is falsely 
classified as a site recognized by multiple kinases, instead of by one true kinase, and if a variation affects only 
some of these kinases, this is a type II phosphovariant incorrectly predicted to be a type III phosphovariant. 
Other points that must be improved are the low sensitivity achieved with the high-specificity option and the low 
specificity achieved with the no-specificity option of PredPhospho (Table 4). Moreover, the number of types of 
kinases that we can predict must be increased and haplotypes should be considered in future studies. 
Our method can be used in pathophysiological studies of mutations and in the selection of polymorphisms 
of clinical and phenotypical importance. Many of the papers that have described the variations, shown in Tables 
1–3, did not mention that the variations could be related to changes in phosphorylation sites. This could be 
attributable to the lack of a specific database that connects mutations with phosphorylation sites, or the lack of a 
general understanding of the association between phosphorylation and mutation. The type I (+), II, and III 
phosphovariants we have defined cannot be identified simply by database analyses. Specific programs are 
required to identify these phosphovariants. Accordingly, many nonsense point mutations whose functional 
mechanisms are unknown can be reconsidered in terms of phosphovariant. Furthermore, if some mutations are 
predicted to be phosphovariants with our system, further research will clarify the cause of the associated disease 
or protein function. Our system can be used to select meaningful variations among endless numbers of newly 
identified polymorphisms. As sequencing techniques advance, a large number of genetic variations are 
emerging. At present, comparison of whole genomes of individuals is possible, because the human genome can 
be sequenced in two months24. A comparison of phosphovariants between individuals or between species can be 
undertaken before amino acid variations or nucleic acid variations are compared in whole genomes. A reverse 
genetic approach for unknown protein functions or phenotypic variations is possible with proven 
phosphovariants. The screening and prediction of phosphovariants can be a starting point for further research. 
Methods 
PredPhospho 
We created classifiers of various kinases by training SVMs with phosphorylation site sequences and 
nonphosphorylated site sequences. In other words, our classifiers determine whether serine, threonine, or 
tyrosine residues within a sequence can be phosphorylated or not. “Phosphorylated site sequences” refers to 
peptide sequences with a serine, threonine, or tyrosine residue located at the center, and which are 
phosphorylated. Conversely, “nonphosphorylated site sequences” are sequences with a serine, threonine, or 
tyrosine residue located at the center, which cannot be phosphorylated. We obtained phosphorylated site 
sequences from public databases: the Swiss-Prot (release 54.8) and the Human Protein Resource Database 
(HPRD, release 7). Nonphosphorylated site sequences were taken from laboratory data confirmed by MS (see 
Supplementary Material online). 
Manning et al. found 518 human protein kinase genes in the human genome sequence, using the hidden 
Markov model (HMM) profile, and confirmed the identities of more than 90% of the identified kinase genes 
using cDNA cloning25. They also classified the protein kinase superfamily into nine broad groups, and 
subdivided the groups into 134 families and 204 subfamilies, using sequence comparisons of the kinase catalytic 
domains. We classified the phosphorylated site sequences according to their kinases and created the classifiers in 
a kinase-specific manner. Because of the limitations of the phosphorylated sequence data presently available in 
public databases, we can make classifiers for only six kinase groups: AGC, CAMK, CK1, CMGC, STE, and TK; 
and 18 kinase families: AKT, CAMK2, CAMKL, CDK, CK1, CK2, GSK, IKK, JakA, MAPK, PDGFR, PIKK, 
PKA, PKC, RSK, Src, STE20, and Syk (all abbreviations are shown in the footnote to Supplementary Table 1 
online). The detailed algorithms and methods were described in the Supplementary Material (online). 
Evaluation of the system 
The performance status of the prediction for each kinase group and family is shown in Supplementary 
Table 2 (online). The performance of the prediction with combinations of all the kinase group models or all the 
family group models is not the numerical multiplication of the performance of each model. Therefore, to 
evaluate the performances of the predictions at the kinase group level or at the family level, we tested two 
proven real data sets, which were compiled with MS experiments. Data set I was created by Olen et al.5, who 
identified phosphorylation sites in proteins from HeLa cells and classified the phosphopeptides according to their 
definition. Four classes are based on their localization probabilities: < 0.25, 0.25 ≤ <0.75 without kinase motifs, 
0.25 ≤ <0.75 with kinase motifs and ≥ 0.75. We used only monophosphopeptides that had localization 
probabilities of at least 0.75. Data set II was derived from the paper of Beausoleil et al.4 and we used those of 
their phosphopeptides with a localization certainty of > 99.4% (see Supplementary Fig. 2 online). We selected 
phosphorylation sites and nonphosphorylated sites from these two data sets. To avoid overestimating the 
performance of PredPhospho, we discarded sequences that were more than 70% identical to  sequences used for 
training PredPhospho. We also avoided using false nonphosphorylated sites by omitting those sites that are listed 
as phosphorylation sites in Swiss-Prot or HPRD. We tested the two kinds of data sets not only with our 
PredPhospho, but also with Scansite. 
Prediction of phosphovariants 
We extracted information about human genetic variations from SwissVariant of the Swiss-Prot database. 
SwissVariant includes single amino acid polymorphisms and missense mutations26. The number of variations 
listed in SwissVariant was 33,651. We consulted the Swiss-Prot database and HPRD about their effects, and the 
references to these variations and phosphorylation sites. With PredPhospho and Scansite, we predicted the 
phosphorylation sites and related kinases for the original sequences and the variant sequences. The 
phosphovariants could be identified when the phosphorylation sites or interacting kinases were altered between 
the original sequence and the variant sequence. If the phosphorylation site is in the same location as the 
variation, it is type I. In type II phosphovariants, the variation is not in the same location as the phosphorylation 
site. We added the symbol (+) to types I and II when the phosphovariants added new phosphorylation sites, and 
(–) when the phosphovariants removed phosphorylation sites [e.g., type I (+] or type I (–)]. Type III 
phosphovariants are caused by changes in the types of kinases involved, rather than in the phosphorylation site 
itself, regardless of the locations of the variations. One variation can include more than one class of 
phosphovariant, because one variation can affect two or more phosphorylation sites. We predicted 
phosphovariants at the kinase group level and the family level. The predictions at the family level are more 
sensitive, but less specific, than those at the group level. To minimize false negatives, we varied the specificity 
options (95%, 97%, 98%, or 99%) according to the specificity of each model (Supplementary Table 3 online). 
The specificity options are described in the Supplementary Material (online). 
Sequence logos 
We obtained 562 phosphorylation site sequences recognized by the CMGC kinase group from Swiss-
Prot and HPRD. We trimmed the sequences as 6 symmetric residues centered phospohrylation sites. We aligned 
the sequences and obtained a sequence logo using the web program (http://weblogo.berkeley.edu/logo.cgi). 
WWW programs 
The PredPhospho (version 2) and PhosphoVariant were implemented using the PERL (version 5.8.8) 
programming language and MySQL (version 5.0.18). The PhosphoVariant is a database for the definite and 
possible human variants changing phosphorylation sites and their interacting kinases. They are available at 
http://phosphovariant.ngri.go.kr/seq_input_predphospho2.htm and http://phosphovariant.ngri.go.kr, respectively. 
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 Table 1 Examples of type I phosphovariants 
(a) Type I(−) phosphovariants 
Gene 
name 
SWISS-
PROT ID 
Variation sitea 
(SWISS-PROT 
variant ID) 
Phosphor-
ylation site 
Effectb 
Reference(s) 
for 
variationc 
Reference(s) 
for phosphor-
ylation sited 
Phosphovariants causing Mendelian inheritant diseases 
EDNRB P24530 
S305N 
(VAR_003472) 
S305 Hirschsprung disease type 2 8852659 14636059 
FANCA O15360 
S858R 
(VAR_017498) 
S858 Fanconi anemia 
10094191 
11091222 
17924679 
KCNJ1 P48048 
S219R 
(VAR_019726) 
S219 Bartter syndrome type 2 8841184 8621594 
L1CAM P32004 
S1194L 
(VAR_003947) 
S1194 
Hydrocephalus due to 
stenosis of the aqueduct of 
Sylvius 
Mental retardation, aphasia, 
shuffling gait, and adducted 
thumbs syndrome 
8556302 
7881431 
17081983 
MAPT P10636 
S622N 
(VAR_010350) 
S622 
Frontotemporal dementia 
and parkinsonism linked 
chromosome 17 
10208578 7706316 
MAPT P10636 
S637F 
(VAR_019665) 
S637 Pick disease 11891833 
11104762 
9199504 
MAPT P10636 
S669L 
(VAR_019667) 
S669 
Fatal respiratory 
hypoventilation 
14595660 11104762 
MITF O75030 
S405P 
(VAR_010302) 
S405 
Waardenburg syndrome 
type IIa 
8589691 10587587 
NFKBIA P25963 
S32I 
(VAR_034871) 
S32 
Autosomal dominant 
anhidrotic ectodermal 
dysplasia with 
immunodeficiency 
14523047 
10882136 
9721103 
8601309 
16319058 
10723127 
9214631 
PER2 O15055 
S662G 
(VAR_029080) 
S662 
Familial advanced sleep-
phase syndrome 
11232563 11232563 
PTPN11 Q06124 
Y62D 
(VAR_015605) 
Y62 
Patients with Noonan 
syndrome 1 manifesting 
juvenile myelomonocytic 
leukemia 
11992261 
12325025 
12960218 
12717436 
15951569 
15592455 
RAF1 P04049 
S259F 
(VAR_037809) 
S259 Noonan syndrome type 5 17603483 
8349614 
11997508 
11971957 
10576742 
RAF1 P04049 
T491R 
(VAR_037819) 
T491 Noonan syndrome type 5 17603483 11447113 
RAF1 P04049 
T491I 
(VAR_037818) 
T491 Noonan syndrome type 5 17603483 11447113 
RPS6KA3 P51812 
S227A 
(VAR_006195) 
S227 Coffin-Lowry syndrome 8955270 17192257 
STAT3 P40763 
Y657C 
(VAR_037381) 
Y657 
Hyperimmunoglobulin E 
recurrent infection 
syndrome autosomal 
dominant 
17881745 15037656 
TGFBR2 P37173 
Y336N 
(VAR_022352) 
Y336 
Loeys-Dietz aortic 
aneurysm syndrome 
15731757 9169454 
TNNI3 P19429 
S166F 
(VAR_029454) 
S166 
Hypertrophic 
cardiomyopathy  
12974739 11121119 
TSC1 Q92574 
T417I 
(VAR_009403) 
T417 
Tuberous sclerosis complex, 
could be a polymorphism 
10570911 
10607950 
14551205 
Phosphovariants found in cancer 
CDH1 P12830 
S838G 
(VAR_001322) 
S838 Ovarian cancer 8075649 10671552 
CTNNB1 P35222 
S23R 
(VAR_017612) 
S23 
Hepatocellular carcinoma, 
no effect 
10435629 
12027456 
12027456 
CTNNB1 P35222 
S33F 
(VAR_017617) 
S33 
Pilomatrixoma, 
medulloblastoma and 
hepatocellular carcinoma 
10666372 
10435629 
10192393 
12000790 
12114015 
11818547 
CTNNB1 P35222 
S33L 
(VAR_017618) 
S33 Hepatocellular carcinoma 10435629 
12000790 
12114015 
11818547 
CTNNB1 P35222 
S37A 
(VAR_017624) 
S37 
Medulloblastoma, 
hepatocellular carcinoma 
12027456,1
0435629, 
10666372 
12000790 
12114015 
11818547 
CTNNB1 P35222 
S37C 
(VAR_017625) 
S37 
Pilomatrixoma, 
hepatoblastoma 
9927029, 
10192393 
12000790 
12114015 
11818547 
CTNNB1 P35222 
S37F 
(VAR_017626) 
S37 Pilomatrixoma 10192393 
12000790 
12114015 
11818547 
CTNNB1 P35222 
T41A 
(VAR_017629) 
T41 
Hepatoblastoma and 
hepatocellular carcinoma, 
also in a desmoid tumor 
12051714 
10398436 
9927029 
12027456 
10655994 
10435629 
12051714 
12114015 
11818547 
12000790 
CTNNB1 P35222 
T41I 
(VAR_017630) 
T41 
Pilomatrixoma and 
hepatocellular carcinoma 
10192393 
10435629 
12051714 
12114015 
11818547 
12000790 
CTNNB1 P35222 
S45F 
(VAR_017631) 
S45 Hepatocellular carcinoma 10435629 
12051714 
12000790 
11955436 
CTNNB1 P35222 
S45P 
(VAR_017632) 
S45 Hepatocellular carcinoma 10435629 
12051714 
12000790 
11955436 
FAM10A4 Q8IZP2 
S71L 
(VAR_023644) 
S71 
B-Cell leukemia, multiple 
myeloma, and prostate 
cancer 
12079276 17081983 
MET P08581 
Y1230C 
(VAR_006292) 
Y1230 
Hereditary papillary renal 
carcinoma 
9140397 12475979 
MET P08581 
Y1230H 
(VAR_006293) 
Y1230 
Hereditary papillary renal 
carcinoma 
9140397 12475979 
NME1 P15531 
S120G 
(VAR_004625) 
S120 Neuroblastoma 8047138 8810265 
RB1 P06400 
S567L 
(VAR_005579) 
S567 Retinoblastoma 
10671068 
2594029 
10207050 
TP53 P04637 
T155A 
(VAR_005901) 
T155 Esophageal cancer 1868473 12628923 
Phosphovariants related with polymorphism 
BARD1 Q99728 S186G S186 polymorphism (rs16852741)  15855157 
C10orf11 Q9H2I8 
S153F 
(VAR_033686) 
S153 polymorphism (rs35349706)  16964243 
CTNND1 O60716 
Y217C 
(VAR_020929) 
Y217 polymorphism (rs11570194)  
15592455 
16212419 
CTPS P17812 
S571I 
(VAR_027055) 
S571 polymorphism (rs17856308) 15489334 
16097034 
17081983 
HIF1A Q16665 
T796A 
(VAR_015854) 
T796 polymorphism (rs1802821)  17382325 
INSR P06213 
Y1361C 
(VAR_015933) 
Y1361 polymorphism (rs13306449) 7657032 11401470 
KRT36 O76013 
T315M 
(VAR_020306) 
T315 polymorphism (rs2301354)  17081983 
MYH15 Q9Y2K3 
T1125A 
(VAR_030238) 
T1125 polymorphism (rs3900940)  17081983 
PDLIM5 Q96HC4 
S136F 
(VAR_023779) 
S136 polymorphism (rs2452600)  17287340 
PNN Q9H307 
S671G 
(VAR_023368) 
S671 polymorphism (rs13021) 10095061 17287340 
SUB1 P53999 S11G S11 polymorphism (rs17850527) 15489334 
17081983 
16689930 
SRRM2 Q9UQ35 
S883C 
(VAR_027260) 
S883 polymorphism (rs17136053)  17287340 
TP53 P04637 
S366A 
(VAR_022317) 
S366 Polymorphism  9183006 
 
(b) Type I(+) phosphovariants 
Gene 
name 
SWISS-
PROT ID 
Variation site 
Phosphor-
ylation site 
Effect 
Reference(s) 
for variant 
Reference(s) 
for phosphor-
ylation site 
DDX27 Q96GQ7 G766S S766 Unknown 16565220 16565220 
a Locations and amino acid changes of the variations in the proteins.  
b The meanings or consequences of the variations. We referred to the feature tables of Swiss-Prot for these 
effects. If the polymorphisms are enrolled in dbSNP, the IDs of dbSNP are written in the parentheses. 
c Pubmed ID for the references of the variations 
d Pubmed ID for the references of the phosphorylation sites 
 Protein names which are abbreviated by their gene names: Catenin β-1, CTNNB1; Epithelial cadherin 
[Precursor], CDH1; Probable ATP-dependent RNA helicase DDX27, DDX27; Endothelin B receptor 
[Precursor], EDNRB; Protein FAM10A4, FAM10A4; Fanconi anemia group A protein, FANCA; ATP-sensitive 
inward rectifier potassium channel 1, KCNJ1; Keratin, type I cuticular Ha6, KRT36; Neural cell adhesion 
molecule L1, L1CAM; Microtubule-associated protein tau, MAPT; Hepatocyte growth factor receptor 
[Precursor], MET; Microphthalmia-associated transcription factor, MITF; NF-κ-B inhibitor α, NFKBIA; 
Nucleoside diphosphate kinase A, NME1; Period circadian protein homolog 2, PER2; Tyrosine-protein 
phosphatase non-receptor type 11, PTPN11; RAF proto-oncogene serine/threonine-protein kinase, RAF1; 
Retinoblastoma-associated protein, RB1; Ribosomal protein S6 kinase alpha-3, RPS6KA3; Signal transducer 
and activator of transcription 3, STAT3; TGF-beta receptor type-2 [Precursor], TGFBR2; Cardiac troponin I, 
TNNI3; Cellular tumor antigen p53, TP53; Hamartin, TSC1 
 
 
Table 2 Examples of type II(−) phosphovariants.  
Gene 
name 
SWISS-
PROT ID 
Variation site 
 (SWISS-PROT 
variant ID) 
Removed 
phosphorylation site 
(related kinases) 
Effect 
Reference(s) 
for variant 
Reference(s) 
for phosphor-
ylation site 
DUT P33316 
P100S 
(VAR_022314) 
S99a (CDC2) Polymorphism  
17081983 
8631817 
GJA1 P17302 
P283L 
(VAR_014101) 
S282a (ERK1, 
ERK2 and MAPK7) 
Polymorphism 
(rs2228974) 
 
8631994 
9535905 
PPARG P37231 
P113Q 
(VAR_010724) 
S112b (ERK2, JNK1 
and MAPK8) 
Obesity and 
polymorphism 
(rs1800571) 
9753710 9030579 
RXRA P19793 
P261L 
(VAR_014620) 
S260a (ERK2 and 
MAPK7) 
Polymorphism 
(rs2234960) 
 12048211 
If the variations substitute the proline residues at position +1 relative to the phosphorylation sites into other 
amino acids, the nearby phosphorylation sites recognized by the CMGC kinase group can be eliminated or the 
efficiency of phosphorylation in that site is significantly decreased.  
a The removals of the phosphorylation sites by the variation have not been confirmed by experiments. However, 
the removals of the phosphorylation sites are highly possible because the nearby phosphorylation sites are 
proved to be recognized by the CMGC group. 
b The removal of the phosphorylation site by the variation has been confirmed by a experiment10. 
Protein names which are abbreviated by their gene names: Deoxyuridine 5'-triphosphate nucleotidohydrolase, 
mitochondrial [Precursor], DUT; Gap junction α-1 protein, GJA1; Peroxisome proliferator-activated receptor γ, 
PPARG; Retinoic acid receptor RXR-α, RXRA 
 
 
 
Table 3 Possible examples of type III phosphovariants. 
(a) A possible example of type III phosphovariant 
Gene 
name 
SWISS-
PROT ID 
Variation site 
 (SWISS-PROT 
variant ID) 
Related 
phosphorylation site 
(kinase recognizing 
it) 
Effect 
Reference(s) 
for variant 
Reference(s) 
for phosphor-
ylation site 
PTPN1 P18031 
P387L 
(VAR_022014) 
S386 (CDC2 and 
CK2) 
Low glucose 
tolerance and 
polymorphism 
(rs16995309) 
15919835 
9600099 
8491187 
 
(b) Possible examples of phosphovariants which can be classified as type I or III. 
Gene 
name 
SWISS-
PROT ID 
Variation site 
(SWISS-PROT 
variant ID) 
Related 
phosphorylation site 
Effect 
Reference(s) 
for variant 
Reference(s) 
for phosphor-
ylation site 
BRCA1 P38398 
S1217Y 
(VAR_020695) 
S1217 
Breast cancer 
and breast-
ovarian cancer 
14722926 17081983 
CASP8 Q14790 
S219T 
(VAR_025816) 
S219 
polymorphism 
(rs35976359) 
 17525332 
CDK2 P24941 
Y15S 
(VAR_016157) 
Y15 
polymorphism 
(rs3087335) 
 
1396589 
12912980 
12972555 
15144186 
CTNNB1 P35222 
S33Y 
(VAR_017619) 
S33 Pilomatrixoma 
12027456 
10192393 
12000790 
12114015 
11818547 
CTNNB1 P35222 
S37Y 
(VAR_017627) 
S37 
Hepatocellular 
carcinoma 
10435629 
12000790 
12114015 
11818547 
TEK Q02763 
Y897S 
(VAR_008716) 
Y897 
Dominantly 
inherited venous 
malformations 
10369874 11080633 
XRCC1 P18887 
S485Y 
(VAR_014779) 
S485 
polymorphism 
(rs2307184) 
 15066279 
The reasons why these variations are classified as type III are detailed in the text. 
Protein names which are abbreviated by their gene names: Breast cancer type 1 susceptibility protein; BRCA1; 
Caspase 8, CASP8; Cyclin dependent kinase 2, CDK2; Catenin β-1, CTNNB1; Tyrosine-protein phosphatase 
non-receptor type 1, PTPN1; Angiopoietin-1 receptor [Precursor], TEK; DNA repair protein XRCC1, XRCC1 
 
 
Table 4 The general performance test of the PredPhospho and Scansite for two real data sets 
(a) The number of each data set 
 Data Ia Data IIa 
 (+)b (−)b (+) (−) 
Ser/Thrb 1860 926 3017 315 
Tyrb 38 95 359 11 
 
(b) PredPhospho 
Prediction at the group level Prediction at the family level 
 Data I Data II  Data I Data II 
Specificityc Sn (%) Sp (%) Sn (%) Sp (%) Specificity Sn (%) Sp (%) Sn (%) Sp (%) 
No 79.40 60.62 75.47 61.04 No 95.36 29.29 93.60 30.98 
95% 73.24 72.09 65.76 72.39 95% 92.68 42.80 88.95 46.63 
97% 53.37 80.22 48.31 79.45 97% 88.46 56.81 83.50 57.36 
98% 43.11 89.23 38.92 89.26 98% 82.03 66.80 75.44 62.88 
99% 23.39 95.79 20.05 96.62 99% 73.18 72.67 66.73 72.39 
 
(c) Scansite 
 Data I Data II 
Stringencyd Sn (%) Sp (%) Sn (%) Sp (%) 
Low 84.47 52.60 83.92 57.06 
Medium 48.63 85.21 43.81 87.73 
High 16.39 96.77 13.60 95.71 
a Different data sets compiled with mass spectrometer. See the text for the detail explanation for data set I and II. 
b The types of amino acids located at the center of peptides. We annotated the peptides as (+) if the Ser/Thr or 
Tyr at the center of the peptides is phosphorylated. On contrary, we designated the peptide as (−) if the center of 
the peptides is not phosphorylated. 
c Options of the specificity. For example, ‘99%’ specificity option mean cutoff value is adjusted for each model 
to have 99% specificity, and ‘No’ specificity option means each model has default cutoff value without 
adjustment of specificity (See supplementary material online). 
d Scansite has three levels of stringency: high, medium and low. High stringency involves low sensitivity and 
high specificity, whereas low stringency involves high sensitivity and low specificity.  
Abbreviations: sensitivity, Sn; specificity, Sp 
 
Table 5 The number of the phosphovariants 
(a) The number of the phosphovariants predicted with PredPhospho at the kinase group level 
 Type I(−) Type I(+) Type II(−) Type II(+) Type III 
Specificity      
No 1729 2036 5455 4980 5299 
95% 981 1195 1304 1070 986 
97% 613 778 694 542 401 
98% 314 409 329 213 151 
99% 116 150 98 52 21 
 
(b) The number of the phosphovariants predicted with PredPhospho at the kinase family level 
 Type I(−) Type I(+) Type II(−) Type II(+) Type III 
Specificity      
No 3039 3717 3969 3926 23955 
95% 2379 2910 2882 2840 8113 
97% 1720 2104 1439 1483 2390 
98% 1268 1551 783 862 1213 
99% 946 1180 539 548 638 
 
(c) The number of the phosphovariants predicted with Scansite 
 Type I(−) Type I(+) Type II(−) Type II(+) Type III 
Stringency      
Low 1581 1852 4255 3773 7698 
Medium 443 498 487 384 152 
High 83 128 35 28 1 
 
Table 6 Predicteda phosphovariants whose phosphorylation sites were confirmed in human or orthologous 
proteins 
(a) Type I(−) phosphovariants  
Gene 
name 
SWISS-
PROT ID 
Site 
(SWISS-PROT 
variant ID) 
Related 
phosphorylation site 
Effect 
Reference(s) 
for variant 
Reference(s) 
for phosphor-
ylation site 
ACIN1 Q9UKV3 
S478F 
(VAR_022033) 
S478 
Polymorphism 
(rs3751501) 
 
17242355 
(mouse)b 
MECP2 P51608 
S229L 
(VAR_018200) 
S229 Polymorphism 
10767337 
12872250 
17046689 
(rat)a 
PAH P00439 
S16P 
(VAR_000869) 
S16 Phenylketonuria 
1679029 
2246858 
1301187 
7387651   
(rat) b 
 
(b) Type II(−) phosphovariants 
Gene 
name 
SWISS-
PROT ID 
Site 
(SWISS-PROT 
variant ID) 
Related 
phosphorylation site 
Effect 
Reference(s) 
for variant 
Reference(s) 
for phosphor-
ylation site 
CHGB P05060 
R178Q 
(VAR_020287) 
S183 
Polymorphism 
(rs910122) 
 16807684 
GTSE1 Q9NYZ3 
R506W 
(VAR_024154) 
S504 
Polymorphism 
(rs140054) 
10591208 16964243 
LIG1 P18858 
P52L 
(VAR_020194) 
S51 
Polymorphism 
(rs4987181) 
 16964243 
 
(c) Type III phosphovariant 
Gene name 
SWISS-
PROT 
ID 
Site 
(SWISS-PROT 
variant ID) 
Related 
phosphorylation 
site1 
Effect 
Reference(s) 
for variant 
Reference(s) 
for phosphor-
ylation site 
ABCB11 O95342 
R698H 
(VAR_035352) 
S701 Polymorphism 16763017 
17242355 
(mouse) b 
ABL1 P00519 
P810L 
(VAR_032678) 
S809  Polymorphism 17344846 17081983 
AQP2 P41181 
P262L 
(VAR_015255) 
S261  
Nephrogenic 
diabetes 
insipidus 
9550615 
15509592 
16641100  
(rat) b 
CASP8 Q14790 
S219T 
(VAR_025816) 
S219 
Polymorphism 
(rs35976359) 
 17525332 
EIF4G3 O43432 
P496A 
(VAR_034009) 
S495 
Polymorphism 
(rs35176330) 
 
17081983 
16964243 
MYBPC3 Q14896 
G278E 
(VAR_019891) 
S275 
Familial 
hypertrophic 
12707239 
9784245 
(chicken)b 
cardiomyopathy 
type 4 
PKMYT1 Q99640 
R140C 
(VAR_019928) 
S143  
Polymorphism 
(rs4149796) 
 17192257 
PPP1R12B O60237 
R836K 
(VAR_024177) 
S839  
Polymorphism 
(rs3881953) 
 
17242355 
(mouse)b  
PARK7 Q99497 
E64D 
(VAR_020493) 
Y67 
Autosomal 
recessive early-
onset Parkinson 
disease 7 
15365989 
14607841 
15592455 
PNN Q9H307 
S671G 
(VAR_023368) 
S667  
Polymorphism 
(rs13021) 
10095061 17287340 
SH3PXD2A Q5TCZ1 
R1035Q 
(VAR_030782) 
S1038  
Polymorphism 
(rs3781365) 
 17525332 
WDR91 A4D1P6 
L257P 
(VAR_033358) 
S256  
Polymorphism 
(rs292592) 
15489334 
14702039 
16964243 
Eight of the type I(−) phosphovariants (VAR_006195, VAR_023368, VAR_023779, VAR_023644, 
VAR_030238, VAR_020306, VAR_033686, and VAR_027260), and a type III phosphovariant (VAR_020695) 
were also predicted. However, their detail information are already written in Table 1 and 3. 
a The prediction was done with the 99% specificity option of PredPhospho at the kinase family level. 
b The experiment was done in the proteins of other than human. The names of the species are written in the 
parenthesis. 
Protein names which are abbreviated by their gene names: Proto-oncogene tyrosine-protein kinase ABL1, 
ABL1; ATP-binding cassette sub-family B member 11, ABCB11; Apoptotic chromatin condensation inducer in 
the nucleus, ACIN1; Aquaporin-2, AQP2; Caspase-8 [Precursor], CASP8; Secretogranin-1 [precusor], CHGB; 
Eukaryotic translation initiation factor 4 gamma 3, EIF4G3; G2 and S phase-expressed protein 1, GTSE1; Zinc 
finger protein KIAA1802, KIAA1802; DNA ligase 1, LIG1; Methyl-CpG-binding protein 2, MECP2; Myosin-
binding protein C, cardiac-type, MYBPC3; Phenylalanine-4-hydroxylase, PAH; Parkinson disease protein 7, 
PARK7; Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase, PKMYT1; Pinin, PNN; 
Protein phosphatase 1 regulatory subunit 12B, PPP1R12B; Ribosomal protein S6 kinase alpha-3, RPS6KA3; 
SH3 and PX domain-containing protein 2A, SH3PXD2A; WD repeat-containing protein 91, WDR91 
 
 
 
 
Figure legends 
Figure 1. Schematic illustration of phosphovariants according to their types. 
Figure 2. Sequence logos of amino acid sequences near phosphorylation sites recognized by the CMGC 
kinase group. 
The horizontal axis represents sequential positions relative to the phosphorylation site. The vertical axis 
represents decreases in uncertainty. Each letter refers to an amino acid. As the frequency of an amino acid at a 
given position increases, its height increases. 
 
 


